Twist Bioscience Corp
For the period ended Jun 30, 2025. Filed Aug 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
| (In thousands, except per share data) | June 30,2025 | September 30,2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $201,373 | $226,316 |
| Short-term investments | 49,425 | 50,083 |
| Accounts receivable, net [1] | 49,854 | 34,903 |
| Inventories | 25,938 | 24,078 |
| Prepaid expenses and other current assets [2] | 13,186 | 11,396 |
| Total current assets | $339,776 | $346,776 |
| Property and equipment, net | 95,351 | 102,520 |
| Operating lease right-of-use assets | 51,845 | 58,829 |
| Investment in equity securities | 54,337 | 1,525 |
| Goodwill | 82,195 | 85,811 |
| Intangible assets, net | 13,688 | 14,478 |
| Restricted cash, non-current | 2,532 | 2,816 |
| Other non-current assets [3] | 3,881 | 1,568 |
| Total assets | $643,605 | $614,323 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $11,985 | $1,630 |
| Accrued expenses | 19,535 | 15,104 |
| Accrued compensation | 28,972 | 33,650 |
| Current portion of operating lease liability | 15,501 | 14,805 |
| Other current liabilities | 11,077 | 5,817 |
| Total current liabilities | $87,070 | $71,006 |
| Operating lease liability, net of current portion | 62,649 | 70,221 |
| Liability related to the sale of future revenue | 15,000 | — |
| Other non-current liabilities[4] | 688 | 407 |
| Total liabilities | $165,407 | $141,634 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value —200,000 and 100,000 shares authorized at June 30, 2025 and September 30, 2024, respectively; 60,174 and 58,877 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively | $— | $— |
| Additional paid-in capital | 1,771,502 | 1,715,119 |
| Accumulated other comprehensive income/(loss) | (864) | (522) |
| Accumulated deficit | (1,292,440) | (1,241,908) |
| Total stockholders’ equity | $478,198 | $472,689 |
| Total liabilities and stockholders’ equity | $643,605 | $614,323 |
[1] Including related parties' balances of $1.2 million and $0.5 million as of June 30, 2025 and September 30, 2024, respectively.
[2] Including related party balances of $1.7 million and $— as of June 30, 2025 and September 30, 2024, respectively.
[3] Including related party balances of $1.7 million and $— as of June 30, 2025 and September 30, 2024, respectively.
[4]Including related party balances of $0.2 million and $— as of June 30, 2025 and September 30, 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.